Navigation Links
Know Your Odds for Heart Failure
Date:6/8/2009

amber wall.

In fact, "people with fewer risk factors had almost no increase in left ventricular mass with age," Vasan noted. "People who had more risk factors had a steeper increase in left ventricular mass with age."

Another advance, outlined in the second study, is a kind of "calculator" that allows for longer-term assessment of a young patient's odds for heart failure, said Michael J. Pencina, associate professor of biostatistics at Boston University, and a co-author of the report with Vasan.

"Until now, risk prediction and risk assessment are based on 10-year and shorter periods," Pencina said. "We are proposing a 30-year risk calculator. It will be a useful development for people aged 20 to 30 who want a fuller picture of what is happening to them."

The calculator, which will be made available through the American Heart Association, will allow most people to determine where they stand, compared both to the population at large and to the ideal, Pencina said.

"We give an optimal profile and also a normal profile," he said. "The normal profile is not quite within the recommended guidelines, but what we see in the general population. If the individual profile exceeds the optimal or normal profile, the individual should contact a physician and talk about the risk factors, what levels they should be at, and whether the physician might recommend lifestyle or other interventions."

Alongside those reports, the American Heart Association issued two scientific advisory statements for people at high risk of heart failure.

One of them was aimed at people with type 2 diabetes. According to the AHA, these individuals should perform at least two-and-a-half hours of moderate-intensity exercise or one-and-a-half hours of vigorous aerobic exercise each week, plus weight training.

The second advisory warned against use of just the body mass index (BMI) to determine obesity. BMI, which is weight in kilo
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2 3

Related medicine news :

1. Members of National CHD Organization Unite for Little Hearts Celebration and Assemble for Picture of Hope
2. Over 2 Million U.S. Adults at Risk of Heart Attacks from Vulnerable Plaque
3. Drugs Best First Defense Against Heart Disease for Diabetics
4. Death rates same for diabetes and heart disease patients receiving drug therapy or surgery
5. Avandia Raises Risk of Heart Failure, Fractures
6. Crowded emergency departments pose greater risks for patients with heart attacks
7. UT Southwesterns Olson wins prestigious French award for heart research
8. Importance of preventing congestion in heart failure
9. QIO Support Accelerates Hospital Improvement in Heart Care, Researchers Find
10. Heart Drug Combos Raise Risk of Gastrointestinal Bleeding
11. First heart patients implanted with next-generation mechanical heart pump
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Know Your Odds for Heart Failure
Know Your Odds for Heart Failure
Breaking Medicine News(10 mins):Health News:Kaiser Permanente Gives $5 Million to Children's Healthcare of Atlanta 2Health News:Kaiser Permanente Gives $5 Million to Children's Healthcare of Atlanta 3Health News:Blues CEO Encourages Graduates to Stay and Lead Michigan 2Health News:Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign 2Health News:Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign 3Health News:Bears Quarterback Jay Cutler and Eli Lilly and Company Will Send 44 Kids to American Diabetes Association Camps Through the Touchdowns for Diabetes Campaign 4Health News:Blood stem-cell transplant regimen reverses sickle cell disease in adults 2Health News:Blood stem-cell transplant regimen reverses sickle cell disease in adults 3Health News:Blood stem-cell transplant regimen reverses sickle cell disease in adults 4Health News:NICE guidelines ration affordable osteoporosis drugs 2Health News:NICE guidelines ration affordable osteoporosis drugs 3
Breaking Medicine Technology:The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 1The First SamarionSolution Installed in Lake Charles Alzheimers Facility 53237 2Blue Cross and Blue Shield of Texas Collaborates With Five Blue Plans to Increase Transparency Expand Access to Health Care Cost Information 53234 1Blue Cross and Blue Shield of Texas Collaborates With Five Blue Plans to Increase Transparency Expand Access to Health Care Cost Information 53234 2Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 1Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 2Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 3Montefiore Medical Center and Albert Einstein College of Medicine Herald New Agreement To Continue Forty Plus Year Historic Relationship 4796 4
Other Medicine Technology:Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 2Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 3Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 4Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 5Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 6Concomitant Treatment With Nebulized Formoterol Fumarate and Tiotropium Provides Clinically Significant Improvements for COPD Patients 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 2New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 3New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 4New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 5New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 6New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 7New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease 8